Business briefs – News – The Hutchinson News

Free dental care offered to Veterans

The dental office of Drs. Travis Gillespie and Mary Brummett, 200 E. 30th Ave., will participate in Veterans Smile Day, providing free dental care to veterans on Nov. 8.

The free services include dental exams, cleanings, fillings, and tooth extractions.

Any veteran in the Hutchinson area needing dental care can call (620) 663-9133 for an appointment or visit https://www.hutchdental.com. An appointment is required for the free service.

Free Google digital marketing seminar inHutchinson

A valuable opportunity for business owners interested in learning how to expand their advertising reach will be coming to Hutchinson.

The Hutchinson News, McPherson Sentinel, The Newton Kansan, and ThriveHive digital marketing service, in partnership with Google, will host Put Your Business on Top, a digital marketing seminar from 8:30 to 10:30 a.m., Nov. 5 at the Cosmosphere.

The seminar will be led by a Google Certified Speaker who will share tips and tricks for using digital marketing to reach qualified customers, impact their purchase decisions, drive sales, and grow a business using online resources. Breakfast is provided during the seminar free of charge.

We will help business owners make strategic decisions about their marketing campaigns and ad spending, said Bob Musilek, Digital Director for Gatehouse Media. We can also help business owners with data insights into their unique audiences interests, habits, and what theyre actively planning to purchase.

The seminar also will include information on retargeting, which refers to re-engaging a potential customer who has visited a website in the past. Retargeting keeps a business fresh in the consumers mind and also builds confidence in a brand as ads for the company make repeat appearances.

Attendees will be able to ask questions about how to seek out new customers, as well as receive tips on how to stand out in a cluttered online marketplace.

They will also receive a free, no-obligation digital audit of their companys website, and business owners will be enrolled in a drawing for one of five certificates worth $500 of digital advertising on TheHutchiNews.com | TheMcPearsonSentinal.com | TheKansan.com.

Register today at hutchnews-events.com to reserve a spot or call (620) 694-5700, ext. 222 or 620-727-4045.

Great Bend Campus offers expert emergency care around the clock

GREAT BEND Even though they arent physically present in the Emergency Department at Great Bend Campus, specialty-trained physicians are now available to patients at all times.

The University of Kansas Health System Great Bend Campus recently became equipped with Avera eCARE. This telemedicine service means a physician trained in emergency medicine is available 24 hours a day, seven days a week.

There is no extra charge to the patient for this service.

We now have access to Avera eCARE providers anytime day or night, said Mark Van Norden, DO, medical director of the Great Bend Campus Emergency Department. They dont have to be in-house to share their expertise.

Avera eCARE is most often used in cases of stroke, sepsis, cardiac events and trauma.

It can be used for any condition, but those four time-critical categories are the most common, noted Dr. Van Norden, who was an advisor during the preliminary work with Avera.

Avera eCARE physicians offer consultations in real-time and are virtually face-to-face with local providers via a television screen.

Avera eCARE offers one of the largest telehealth networks in the United States. Based in Sioux Falls, South Dakota, it supports more than 380 healthcare facilities, clinics, long-term-care centers and corrections facilities in 14 states.

Veterans Day Dinner with the Doctors

NEWTON Newton Medical Center is inviting the public to a Veterans Day Dinner with the Doctor on Nov. 11.

Retired orthopedic surgeon Charles Craig, family medicine physician Spencer Duncan and OBGYN physician Jackson Sobbing will present on stem cell therapy and how it may affect chronic pain management. Attending veterans will also be honored during the presentation.

The dinner at Newton Medical Centers Sunflower Caf, 600 Medical Center Dr., starts at 5:30 p.m. and the presentation at 6 p.m. The cost is $7, though Veterans eat free. RSVP for dinner at (316) 804-6129.

LifeSave Transport and Salina Airport Authority host ribbon cutting

SALINA The Salina Airport Authority and LifeSave Transport, a ground and critical care air transport company, will be hosting a ribbon-cutting and open house from 3:30 p.m. to 5:30 p.m. Thursday at 2013 Kneubuhl Ct., Hangar #504 in Salina.

The ribbon-cutting is scheduled as a celebration of LifeSaves new hangar space and helicopter based out of Salina Regional Airport serving North Central Kansas.

The Salina Airport Authority has been working on hangar renovations to house LifeSaves Bell 206 helicopter and ready-alert crew. The $200,000 investment in improvements included a new fire sprinkler system and completely remodeled crew quarters. The 3:30 p.m. event in LifeSaves hangar will be accompanied by light hors d oeuvres and opportunities to visit with LifeSave and Salina Airport Authority staff.

The location of the new base comes as part of LifeSaves infrastructure plan supporting its new role as the Preferred Partner for The University of Kansas Health Systems Care Collaborative to increase service availability for member hospitals located in North Central Kansas.

The independently owned medical transport system founded by Kansas emergency physicians operates emergency transport aircraft in Dodge City, Emporia, Garden City, Liberal, Colby, and Salina, and in McCook, Nebraska, with ground transport vehicles in Wichita and Dodge City.

SBA seeks input on changes to its Export Loan Programs

WASHINGTON The U.S. Small Business Administration published an Advanced Notice of Proposed Rulemaking that seeks comments on possible changes to the regulations governing its Export Loan Programs.

SBAs Export Loan Programs provide access to capital for U.S. small business concerns to support expansion into international markets and the growth of U.S. small business exports. SBA is soliciting comments on how the Agency can improve the products, procedures, forms, and reporting requirements of the Export Loan Programs.

Feedback will be used to modernize the Export Loan Programs, increase lender participation and usage, ensure that U.S. small businesses can finance their international sales, and increase U.S. small business exports.

The comment deadline is Nov. 18. To submit, visit: https://www.federalregister.gov/documents/2019/09/17/2019-20048/export-express-export-working-capital-and-international-trade-loan-programs.

To learn more about how the SBA supports U.S. small business exporters, visit https://www.sba.gov/offices/headquarters/oit.

Great Bend Walmart Supercenter remodel complete

GREAT BEND Great Bend residents got their first look at the newly remodeled Walmart Supercenter, 3503 10th Street, during a grand reopening celebration Friday.

Headlining the remodel is the launch of a Pickup Tower.

Pickup Towers are 16-feet-tall and function like high-tech vending machines, capable of fulfilling a customers online order in less than a minute. To use the tower, customers choose from millions of items available on Walmart.com and select the Pickup option at checkout. When the item arrives at the local store, an associate loads it into the Pickup Tower, and the customer retrieves it by scanning a bar code sent to their smartphone. Customers will also enjoy the following store improvements:

State-of-the-art electronics department with interactive displays

New tool department with a new look and added variety of tools

Self-checkouts at the front of the store to save customers time

Updated apparel departments with new signage and fitting rooms

New layout and larger assortment in the Home department

Early dinner at Olive Garden

With the return to Standard Central Time on Nov. 3, Olive Garden is offering a way to enjoy dinner earlier and at a value.

On Monday through Thursday, from 3 to 5 p.m., Olive Garden will offer Early Dinner Duos the perfect cure for those adjusting to the time change. Guests may choose from over 50 combinations of popular favorites like Fettucine Alfredo and Chicken Parmigiana, paired with soup or salad and all the breadsticks that you want, starting at just $8.99.

Follow this link:
Business briefs - News - The Hutchinson News

BEYOND LOCAL: Expert recommends ‘path of cautious optimism’ about the future of stem cell treatment – CollingwoodToday

This article, written byKatharine Sedivy-Haley, University of British Columbia, originally appeared on The Conversation and is republished here with permission:

When I was applying to graduate school in 2012, it felt like stem cells were about to revolutionize medicine.

Stem cells have the ability to renew themselves, and mature into specialized cells like heart or brain cells. This allows them to multiply and repair damage.

If stem cell genes are edited to fix defects causing diseases like anemia or immune deficiency, healthy cells can theoretically be reintroduced into a patient, thereby eliminating or preventing a disease. If these stem cells are taken or made from the patient themselves, they are a perfect genetic match for that individual, which means their body will not reject the tissue transplant.

Because of this potential, I was excited that my PhD project at the University of British Columbia gave me the opportunity to work with stem cells.

However, stem cell hype has led some to pay thousands of dollars on advertised stem cell treatments that promise to cure ailments from arthritis to Parkinsons disease. These treatments often dont help and may harm patients.

Despite the potential for stem cells to improve medicine, there are many challenges as they move from lab to clinic. In general, stem cell treatment requires we have a good understanding of stem cell types and how they mature. We also need stem cell culturing methods that will reliably produce large quantities of pure cells. And we need to figure out the correct cell dose and deliver it to the right part of the body.

Embryonic, 'induced and pluripotent

Stem cells come in multiple types. Embryonic stem cells come from embryos which makes them controversial to obtain.

A newly discovered stem cell type is the induced pluripotent stem cell. These cells are created by collecting adult cells, such as skin cells, and reprogramming them by inserting control genes which activate or induce a state similar to embryonic stem cells. This embryo-like state of having the versatile potential to turn into any adult cell type, is called being pluripotent.

However, induced pluripotent and embryonic stem cells can form tumours. Induced pluripotent stem cells carry a particularly high risk of harmful mutation and cancer because of their genetic instability and changes introduced during reprogramming.

Genetic damage could be avoided by using younger tissues such as umbilical cord blood, avoiding tissues that might contain pre-existing mutations (like sun-damaged skin cells), and using better methods for reprogramming.

Stem cells used to test drugs

For now, safety concerns mean pluripotent cells have barely made it to the clinic, but they have been used to test drugs.

For drug research, it is valuable yet often difficult to get research samples with specific disease-causing mutations; for example, brain cells from people with amyotrophic lateral sclerosis (ALS).

Researchers can, however, take a skin cell sample from a patient, create an induced pluripotent stem-cell line with their mutation and then make neurons out of those stem cells. This provides a renewable source of cells affected by the disease.

This approach could also be used for personalized medicine, testing how a particular patient will respond to different drugs for conditions like heart disease.

Vision loss from fat stem cells

Stem cells can also be found in adults. While embryonic stem cells can turn into any cell in the body, aside from rare newly discovered exceptions, adult stem cells mostly turn into a subset of mature adult cells.

For example, hematopoietic stem cells in blood and bone marrow can turn into any blood cell and are widely used in treating certain cancers and blood disorders.

A major challenge with adult stem cells is getting the right kind of stem cell in useful quantities. This is particularly difficult with eye and nerve cells. Most research is done with accessible stem cell types, like stem cells from fat.

Fat stem cells are also used in stem cell clinics without proper oversight or safety testing. Three patients experienced severe vision loss after having these cells injected into their eyes. There is little evidence that fat stem cells can turn into retinal cells.

Clinical complications

Currently, stem cell based treatments are still mostly experimental, and while some results are encouraging, several clinical trials have failed.

In the brain, despite progress in developing treatment for genetic disorders and spinal cord injury, treatments for stroke have been unsuccessful. Results might depend on method of stem cell delivery, timing of treatment and age and health of the patient. Frustratingly, older and sicker tissues may be more resistant to treatment.

For eye conditions, a treatment using adult stem cells to treat corneal injuries has recently been approved. A treatment for macular degeneration using cells derived from induced pluripotent stem cells is in progress, though it had to be redesigned due to concerns about cancer-causing mutations.

A path of cautious optimism

While scientists have good reason to be interested in stem cells, miracle cures are not right around the corner. There are many questions about how to implement treatments to provide benefit safely.

In some cases, advertised stem cell treatments may not actually use stem cells. Recent research suggests mesenchymal stem cells, which are commonly isolated from fat, are really a mixture of cells. These cells have regenerative properties, but may or may not include actual stem cells. Calling something a stem cell treatment is great marketing, but without regulation patients dont know what theyre getting.

Members of the public (and grad students) are advised to moderate their excitement in favour of cautious optimism.

Katharine Sedivy-Haley, PhD Candidate in Microbiology and Immunology, University of British Columbia

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Here is the original post:
BEYOND LOCAL: Expert recommends 'path of cautious optimism' about the future of stem cell treatment - CollingwoodToday

BEYOND LOCAL: Expert recommends ‘path of cautious optimism’ about the future of stem cell treatment – NewmarketToday.ca

This article, written byKatharine Sedivy-Haley, University of British Columbia, originally appeared on The Conversation and is republished here with permission:

When I was applying to graduate school in 2012, it felt like stem cells were about to revolutionize medicine.

Stem cells have the ability to renew themselves, and mature into specialized cells like heart or brain cells. This allows them to multiply and repair damage.

If stem cell genes are edited to fix defects causing diseases like anemia or immune deficiency, healthy cells can theoretically be reintroduced into a patient, thereby eliminating or preventing a disease. If these stem cells are taken or made from the patient themselves, they are a perfect genetic match for that individual, which means their body will not reject the tissue transplant.

Because of this potential, I was excited that my PhD project at the University of British Columbia gave me the opportunity to work with stem cells.

However, stem cell hype has led some to pay thousands of dollars on advertised stem cell treatments that promise to cure ailments from arthritis to Parkinsons disease. These treatments often dont help and may harm patients.

Despite the potential for stem cells to improve medicine, there are many challenges as they move from lab to clinic. In general, stem cell treatment requires we have a good understanding of stem cell types and how they mature. We also need stem cell culturing methods that will reliably produce large quantities of pure cells. And we need to figure out the correct cell dose and deliver it to the right part of the body.

Embryonic, 'induced and pluripotent

Stem cells come in multiple types. Embryonic stem cells come from embryos which makes them controversial to obtain.

A newly discovered stem cell type is the induced pluripotent stem cell. These cells are created by collecting adult cells, such as skin cells, and reprogramming them by inserting control genes which activate or induce a state similar to embryonic stem cells. This embryo-like state of having the versatile potential to turn into any adult cell type, is called being pluripotent.

However, induced pluripotent and embryonic stem cells can form tumours. Induced pluripotent stem cells carry a particularly high risk of harmful mutation and cancer because of their genetic instability and changes introduced during reprogramming.

Genetic damage could be avoided by using younger tissues such as umbilical cord blood, avoiding tissues that might contain pre-existing mutations (like sun-damaged skin cells), and using better methods for reprogramming.

Stem cells used to test drugs

For now, safety concerns mean pluripotent cells have barely made it to the clinic, but they have been used to test drugs.

For drug research, it is valuable yet often difficult to get research samples with specific disease-causing mutations; for example, brain cells from people with amyotrophic lateral sclerosis (ALS).

Researchers can, however, take a skin cell sample from a patient, create an induced pluripotent stem-cell line with their mutation and then make neurons out of those stem cells. This provides a renewable source of cells affected by the disease.

This approach could also be used for personalized medicine, testing how a particular patient will respond to different drugs for conditions like heart disease.

Vision loss from fat stem cells

Stem cells can also be found in adults. While embryonic stem cells can turn into any cell in the body, aside from rare newly discovered exceptions, adult stem cells mostly turn into a subset of mature adult cells.

For example, hematopoietic stem cells in blood and bone marrow can turn into any blood cell and are widely used in treating certain cancers and blood disorders.

A major challenge with adult stem cells is getting the right kind of stem cell in useful quantities. This is particularly difficult with eye and nerve cells. Most research is done with accessible stem cell types, like stem cells from fat.

Fat stem cells are also used in stem cell clinics without proper oversight or safety testing. Three patients experienced severe vision loss after having these cells injected into their eyes. There is little evidence that fat stem cells can turn into retinal cells.

Clinical complications

Currently, stem cell based treatments are still mostly experimental, and while some results are encouraging, several clinical trials have failed.

In the brain, despite progress in developing treatment for genetic disorders and spinal cord injury, treatments for stroke have been unsuccessful. Results might depend on method of stem cell delivery, timing of treatment and age and health of the patient. Frustratingly, older and sicker tissues may be more resistant to treatment.

For eye conditions, a treatment using adult stem cells to treat corneal injuries has recently been approved. A treatment for macular degeneration using cells derived from induced pluripotent stem cells is in progress, though it had to be redesigned due to concerns about cancer-causing mutations.

A path of cautious optimism

While scientists have good reason to be interested in stem cells, miracle cures are not right around the corner. There are many questions about how to implement treatments to provide benefit safely.

In some cases, advertised stem cell treatments may not actually use stem cells. Recent research suggests mesenchymal stem cells, which are commonly isolated from fat, are really a mixture of cells. These cells have regenerative properties, but may or may not include actual stem cells. Calling something a stem cell treatment is great marketing, but without regulation patients dont know what theyre getting.

Members of the public (and grad students) are advised to moderate their excitement in favour of cautious optimism.

Katharine Sedivy-Haley, PhD Candidate in Microbiology and Immunology, University of British Columbia

This article is republished from The Conversation under a Creative Commons license. Read the original article.

See more here:
BEYOND LOCAL: Expert recommends 'path of cautious optimism' about the future of stem cell treatment - NewmarketToday.ca

Tech review: Apps that enhance cellphone battery performance – Newsday

Another grueling day isnt even close to finished, but your smartphone battery is already more drained than you are. While iPhones and Android devices have built-in battery analyzers, they offer limited information. These apps give you the power to know why your battery is losing strength and lets you take steps to extend its life.

(iOS, Android; free)

One of the few battery apps available in versions for both iPhones and Android devices, Battery HD+ is less of a battery analyzer that it is a battery predictor it tells you how much juice you have left for various tasks. For example, you mighthave power for several hours of internet browsing but far less if you want to watch a video. Battery HD+ calibrates itself to your specific phone to give better estimates of battery time remaining.

(Android; free)

AccuBattery provides detailed statistics on discharging speed, foreground app usage and general battery health without guesswork. Is an ad-heavy app draining too much power over time? AccuBattery can help you find the offending apps that use too much juice and mighthelp you efficiently run your phone longer. AccuBattery also helps in determining whether its not really power-hungry apps that are the problem. It will tell you if your battery may simply need replacing.

The latest LI business news in your inbox Monday through Friday.

By clicking Sign up, you agree to our privacy policy.

(Android; free)

This app from giant anti-virus software maker Avast gets proactive: It finds those power-mad apps running in the background and if you are not using them, it stops them. (Dont worry: They can be easily restarted when you need them.) Avast says its app can help you get 20 percent more out of your battery, so youll be charging a lot less.

(iOS; free)

While newer versions of iOS have a very good stockBattery Health feature, this app drills down farther to examine and analyze your phones battery and make a decision whether it is healthy or failing. It will also tell you how much time you have left to run various tasks. The apps features and effectiveness vary depending on which iPhone and iOS version you have.

John Montgomery contributed to this story.

The owner of Roosevelt Field mall, Walt Whitman Shops and Smith Haven Mall is going big on e-commerce. Simon Property Group, the biggest U.S. mall owner, is testing a new website, shoppremiumoutlets.com, where it will offer online value shopping from its premium outlet malls. Simon owns 107 malls and 69 premium outlets, including Woodbury Common Premium Outlets in upstate New York.

If you expect the automatic emergency braking systems on many new cars to prevent you from hitting a pedestrian, you might be making a fatal mistake. AAA says its research shows the pedestrian detection component of the braking systems fails to operate in many ordinary driving situations and doesn't work at all at night. AAA notes that 75 percent of fatal pedestrian accidents happen after dark.

Responding to ubiquitous online marketing by stem cell clinics selling unapproved treatments for everything from achy joints to Alzheimers, Google said it will no longer accept ads for unproven or experimental medical techniques, including most stem cell therapy, cellular therapy and gene therapy. Google said it was taking the step after seeing a rise in bad actors trying to take advantage of patients by offering untested, deceptive treatments.

By Peter King Special to Newsday

Original post:
Tech review: Apps that enhance cellphone battery performance - Newsday

Better solutions for the replacement of joints – SciTech Europa

Orthopaedic Research focuses on finding solutions for regenerating parts of the musculoskeletal apparatus that often fail while ageing as they are constantly loaded. Hereby, it can be mentioned that the joints who are often involved are the knees with problems such as cartilage degeneration and/or meniscus degeneration, but also ruptures of the anterior cruciate ligament. Furthermore, the rotator-cuff joint of the shoulder and the intervertebral discs of the spine are potentially affected with a very poor self-healing capacity. These problems might arise by ageing but also due to post-trauma induced degeneration or genetic predisposition.

In terms of implants the most successful surgery for Orthopaedics remains the hip implant. Here, complication rates as low as 1-2% were reported. However, for all other joints no equally good solutions exist until now. Here, an improved understanding of the mechano-biology of joints and the tissue homeostasis is needed. Current solutions are often to replace the joint with a full implant. However, these natural joints possess six-degree-of-freedom for motion, e.g. the knee and the spine, but are also equipped with proprio-and mechano-receptors that provide important information about the actual position and movement/loading of the joint.

An increasing elderly population demands for an increased supply of joint substitutes or replacement parts. However, these are unmet clinical needs as implants do not often give back full range of motion and proprioception, which is important for certain movements. Thus, for the intervertebral discs of the spine, cartilage and meniscus, currently no good solutions exist in the clinics that provide long-time satisfaction. Here, tissue engineering is expected to unleash new solutions.

The Tissue Engineering, Orthopaedics & Mechanobiology (TOM) Group of the Department for BioMedical Research (DBMR),at the University of Bern conducts translational research at the intersection of tissue engineering, biology and applied clinical research. The group is experienced in musculoskeletal connective tissues, such as bone, cartilage, ligaments and tendons. The TOM research Group has established core competence how these tissues and/or cells can be targeted and cultured into various 3D systems from biomaterials to organoids.

The primary aims of the TOM group are on the one hand to investigate cell therapy options to regenerate the intervertebral disc (IVD) of the spine and on the other hand, to elucidate bone metabolism and signalling of the bone morphogenic proteins (BMPs) in order to improve patients outcome for spinal fusion. The third focus is the understanding of ruptures of the anterior cruciate ligament of the knee and its options to heal this structure. Here, the aim is to find superior solutions for the healing of the anterior cruciate ligament (ACL).

To achieve these goals, the group applies a broad spectrum of methods, such as cell targeting by sorting, 3D hydrogel culture, organ 3D culture and specialised bioreactors that maintain the joint tissues mechano-biological requirements. The common focus of the TOM group is to advance in vitro organ culture models, which match closely the human situation and where regenerative therapy strategies, such as novel biomaterials and cells, can be tested in a most authentic in vitro set-up.

In regenerative medicine, and especially in tissue engineering, several open questions still need to be tackled, such as which cells or which materials to take for healing and/or regeneration. It would be great if materials could be designed for the recruitment of cells on site-of-request with growth factors that would either induce cell migration or even lead to differentiation of progenitor cells into the correct cell type. In line of this research, many research teams have tried to develop novel smart biomaterials containing growth factors. Indeed, some of these approaches seem to carry potential for further optimisation.

For the IVD, growth and differentiation factor five and six (i.e., GDF5 and GDF6) are especially promising in this respect, as they were shown to be of central relevance for thriving mesenchymal stromal cells (MSCs) towards an IVD phenotype. In this project, silk scaffolds were produced by transduced Bombyx mori (silkworm) cultures with a cassette that contained the human growth factor GDF6.1.

Recent advancements in the field of engineering, such as electro-spinning and/or 3D printing might lead to new options and products. The group has been driving research in the fields of silk electro-spinning in collaboration with Ren Rossi and Guisepino Fortunato from the Empa, St. Gallen, Laboratory for Biomimetic Membranes and Textiles. With these collaborations new protocols were established to generate different scaffolds mimicking either the outer part of the disc, i.e. the annulus fibrosus (AF) with a parallel fibre orientation, using a rotating mandrill to collect the silk fibres in a parallel orientation.

To mimic the inner part a static collector to accumulate randomly oriented fibres, which mimics the centre of the IVD, and scaffolds were seeded with nucleopulpocytes. Here, the basic question was more on the production of fibres and their orientation and mechanical properties for IVD repair.

Furthermore, the group performed in vitro pre-clinical models using genetically engineered silk. This successful Gebert-Rf-founded project involved the collaboration of a German company that produced the silk (Spintec Engineering, GmbH, Aachen, Germany). The project was a collaboration with specific know-how on producing a GMP (general molecular practise)-compliant silk containing two of very promising growth factors for IVD repair.

The feasibility was then tested using in vitro 3D cell culture experiments seeding adult stem cells isolated from the bone-marrow aspirated from spinal surgery at the University Hospital of Bern. Prof Dr Lorin Benneker, head of Spine of the Insel University Hospital of Bern, from the Department of Traumatology and Orthopedics, was involved and provided valuable clinical tissue that allowed to assess the important question whether human primary IVD cells can be expanded with these materials and whether these cells can be stimulated towards.

The feasibility of IVD repair was tested in a 3d explant organ culture model. The team of Prof Dr Gantenbein could show that adult mesenchymal stromal cells from bone marrow could be differentiated towards more intervertebral-disc-like cells producing extra cellular matrix as expected of the so-called nucleopulpocytes.

In terms of repair for the centre of the IVD, the so-called nucleus pulposus, hydrogels are very attractive. Here, it was shown that the mechanical properties of such hydrogels are often not optimised for the orthopaedic application. For IVD and cartilage repair the stiffness of these materials should be adopted to better match the one of a native nucleus pulposus of the human lumbar disc. This increased stiffness could be achieved by incorporation of linkers into the hydrogels such as genipin. This has been tested successfully in the established bioreactor using live bovine IVD explants.

In a recently started European consortium H2020 project named iPSpine, Project number #825925, that is led by Prof Dr Marianna Tryfonidou of the University of Utrecht, the TOM group is contributing knowledge how to target a rare progenitor cell population from the centre of the disc that might be useful for regenerative purposes. The presented findings were related to their recently published work alongside supporting partners of the iPSpine consortium that compares cell sorting methods for bovine cells disc progenitors (Tissue Engineering part C Methods, June 2019). According to the TOM groups findings, Fluorescent Associated Cell Sorting (FACS) was the best isolation method for sorting the tissue specific progenitor cells and led to the most potent and functional cells. The aim is to apply soon this process for therapeutic purposes in humans.

Members of Prof Gantenbeins lab are working to build on these findings within the iPSpine consortium. Dr Julien Guerrero is working on a Standard Operational Protocol for the isolation of these progenitors cells from human intervertebral discs. These cells can then be further considered and employed for the purposes of the iPSpine consortium. Within this consortium it is foreseen to derive GMP-grade specialised cells (induced pluripotent stem cells; iPSCs).

These steps are all advancing the goals of iPSpine to develop an advanced cell therapy to soon ease the widespread health problems of people suffering from chronic low back pain, the most common cause of job-related disability and missed work.

Prof Dr Benjamin Gantenbein and Dr Julien Guerrero

Department for BioMedical Research (DBMR)

Tissue Engineering for Orthopaedics & Mechanobiology (TOM)

Department of Orthopaedics

& Traumatology

Insel University Hospital

University of Bern

+41 31 632 88 15

Benjamin.Gantenbein@dbmr.unibe.ch

Julien.Guerrero@dbmr.unibe.ch

http://www.tom-lab.com

Go here to see the original:
Better solutions for the replacement of joints - SciTech Europa

Google banned ads for stem cell treatments. Others should follow – STAT

Google took an important step this month toward restricting the reach of one breed of 21st-century snake oil purveyor: those selling stem cell treatments. Others need to follow its lead.

More than 600 clinics in the U.S. and many more around the world have co-opted the potential of using stem cell treatments to cure a range of medical conditions and now sell these treatments directly to the public despite a lack of evidence that they work as promised.

Thousands of people have paid for these treatments and received nothing in return or, in some cases, have been seriously harmed or even died. While the FDA and other regulators are increasingly taking action against some of the worst of these businesses, these actions have been slow and the marketplace for unproven stem cell treatments continues to grow.

advertisement

Snake oil salesmen and exploitative medical practitioners are hardly new. But with online advertising, social media, and crowdfunding, they are reaching an ever-enlarging audience. In response to criticism of its role in hosting advertisements for such companies, Google (GOOGL) announced this month it would prohibit advertising for unproven or experimental medical techniques such as most stem cell therapy, cellular (non-stem) therapy, and gene therapy. This is an important step in combating companies selling unproven therapies such as stem cell treatments because they use these advertisements to reach potential customers, often couched in misleading language about the safety and effectiveness of these treatments.

I applaud Googles move to ensure that it is less complicit in exploiting the hopes of seriously ill users. But Google alone cant stop this problem. Even if it could successfully eliminate ads by problematic actors on its services, including YouTube, these companies can turn to other advertising providers to reach the public. They will still be able to represent their brands on Facebook (FB), Twitter, Instagram, and the like, and will appear in search results on Google and other search engines, taking users to websites that are often filled with emotionally gripping testimonials that are light on facts or even distort them. While some platforms have banned companies and groups that spread misinformation via their services, they should be pressured to follow Googles lead and cease promoting unproven treatments that potentially exploit the public.

In addition to addressing direct-to-consumer advertisements, more needs to be done to restrict financing for companies offering stem cell treatments and other unproven therapies. Since public and private insurers will not pay for unproven medical treatments the occasional exception being legitimate clinical trials designed to determine the safety and effectiveness of experimental treatments many people interested in pursuing stem cell and other unproven treatments choose to drain their savings or increasingly turn to crowdfunding to pay for them.

GoFundMe, the dominant crowdfunding platform for medical purposes, could follow Googles lead and prohibit fundraising for unproven medical treatments. In addition to stepping away from being complicit in enabling these companies to flourish, this would prevent crowdfunding campaigns from being used as a vast source of misleading claims about the safety and efficacy of these treatments.

Instead, GoFundMe has chosen not to create a policy of prohibiting such campaigns, but will ban them only if they are either illegal, prohibited, or enjoined by an applicable regulatory body or have been found by an applicable regulatory body to cause consumer harm. This puts the onus on regulators like the FDA to take actions against these companies.

While the FDA can and should be doing more to crack down on businesses selling stem cell treatments and other unproven therapies to the public, companies like GoFundMe and Google know they are being used to exploit their users. The difference is that Google has seen fit to take some action to address this, while other tech companies generally have not.

Without a more united front by tech companies to stop aiding companies that exploit the hopes of people who are desperately ill, then this corruption of science will continue. Even a company as large and powerful as Google cant fix this problem alone. If the major tech companies cant unite to find a solution and continue to profit from this abuse, then there will be increasing need for the government to more actively force the issue for them.

Jeremy Snyder, Ph.D., is a professor in the Faculty of Health Sciences at Simon Fraser University in British Columbia, Canada.

See original here:
Google banned ads for stem cell treatments. Others should follow - STAT

Opinion: Kudos to Google for banning stem cell ads. Other tech companies should follow – Yahoo News

Google took an important step this month toward restricting the reach of one breed of 21st-century snake oil purveyor: those selling stem cell treatments. Others need to follow its lead.

More than 600 clinics in the U.S. and many more around the world have co-opted the potential of using stem cell treatments to cure a range of medical conditions and now sell these treatments directly to the public despite a lack of evidence that they work as promised.

Thousands of people have paid for these treatments and received nothing in return or, in some cases, have been seriously harmed or even died. While the FDA and other regulators are increasingly taking action against some of the worst of these businesses, these actions have been slow and the marketplace for unproven stem cell treatments continues to grow.

Snake oil salesmen and exploitative medical practitioners are hardly new. But with online advertising, social media, and crowdfunding, they are reaching an ever-enlarging audience. In response to criticism of its role in hosting advertisements for such companies, Google announced this month it would prohibit advertising for unproven or experimental medical techniques such as most stem cell therapy, cellular (non-stem) therapy, and gene therapy. This is an important step in combating companies selling unproven therapies such as stem cell treatments because they use these advertisements to reach potential customers, often couched in misleading language about the safety and effectiveness of these treatments.

Read more: In hunt for new drugs, Amazon and other tech giants are using AI to find protein structures

I applaud Googles move to ensure that it is less complicit in exploiting the hopes of seriously ill users. But Google alone cant stop this problem. Even if it could successfully eliminate ads by problematic actors on its services, including YouTube, these companies can turn to other advertising providers to reach the public. They will still be able to represent their brands on Facebook, Twitter, Instagram, and the like, and will appear in search results on Google and other search engines, taking users to websites that are often filled with emotionally gripping testimonials that are light on facts or even distort them. While some platforms have banned companies and groups that spread misinformation via their services, they should be pressured to follow Googles lead and cease promoting unproven treatments that potentially exploit the public.

In addition to addressing direct-to-consumer advertisements, more needs to be done to restrict financing for companies offering stem cell treatments and other unproven therapies. Since public and private insurers will not pay for unproven medical treatments the occasional exception being legitimate clinical trials designed to determine the safety and effectiveness of experimental treatments many people interested in pursuing stem cell and other unproven treatments choose to drain their savings or increasingly turn to crowdfunding to pay for them.

Story continues

GoFundMe, the dominant crowdfunding platform for medical purposes, could follow Googles lead and prohibit fundraising for unproven medical treatments. In addition to stepping away from being complicit in enabling these companies to flourish, this would prevent crowdfunding campaigns from being used as a vast source of misleading claims about the safety and efficacy of these treatments.

Read more: In a CRISPR first, therapy intended to cure HIV patient appears safe though ineffective

Instead, GoFundMe has chosen not to create a policy of prohibiting such campaigns, but will ban them only if they are either illegal, prohibited, or enjoined by an applicable regulatory body or have been found by an applicable regulatory body to cause consumer harm. This puts the onus on regulators like the FDA to take actions against these companies.

While the FDA can and should be doing more to crack down on businesses selling stem cell treatments and other unproven therapies to the public, companies like GoFundMe and Google know they are being used to exploit their users. The difference is that Google has seen fit to take some action to address this, while other tech companies generally have not.

Without a more united front by tech companies to stop aiding companies that exploit the hopes of people who are desperately ill, then this corruption of science will continue. Even a company as large and powerful as Google cant fix this problem alone. If the major tech companies cant unite to find a solution and continue to profit from this abuse, then there will be increasing need for the government to more actively force the issue for them.

Jeremy Snyder, Ph.D., is a professor in the Faculty of Health Sciences at Simon Fraser University in British Columbia, Canada.

Read this article:
Opinion: Kudos to Google for banning stem cell ads. Other tech companies should follow - Yahoo News

Global Canine Stem Cell Therapy Market Data Analysis, Growth, Demand & Forecast 2019-2024: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus,…

The "Canine Stem Cell Therapy Market" research report provides all the point related to global Canine Stem Cell Therapy market commencing from the fundamental market data and moving up towards to various essential factors, based on which, the Canine Stem Cell Therapy market is segregatedone of which is key market players VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet. Major use-case scenarios of Canine Stem Cell Therapy are also evaluated based on their performance.Summary of the Global Canine Stem Cell Therapy Report

Apply here for the free sample copy of the report @: http://www.reportsbuzz.com/request-for-sample.html?repid=74282

The report examines the Canine Stem Cell Therapy market considering the export and import numbers along with the current industry chain. It also covers development and growth of demand & supply of Canine Stem Cell Therapy.Furthermore, The report presents a detailed segmentation Allogeneic Stem Cells, Autologous Stem cells, Market Trend by Application Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes of the global market based on technology, product type, application, and various processes and systems.

The Canine Stem Cell Therapy market research report examines the existing as well as sequential performance of the worldwide market apart from the newest market trends. The report also calculates the forthcoming status of Canine Stem Cell Therapy market based on thorough analysis.

Read Detailed Index of full Research Study at:: http://www.reportsbuzz.com/74282/global-canine-stem-cell-therapy-market-outlook-2018/

Scope of the Global Canine Stem Cell Therapy Report

The Canine Stem Cell Therapy market report comprises each and every property of the global market, which starts from the definition of the Canine Stem Cell Therapy market and ends with the segmentation of the market. The geographical segmentation of the Canine Stem Cell Therapy market has been performed and examined genuinely in this report In addition to this, each section of the Canine Stem Cell Therapy market is segmented and studied on the basis of types of products, their applications, and the end-use firms of the industry The global Canine Stem Cell Therapy market is also studied on the basis of size of manufacturing for Canine Stem Cell Therapy, cost of goods, the revenue created by the products, and data associated with supply & demand of Canine Stem Cell Therapy The competitive situation of the global Canine Stem Cell Therapy market is conducted on the basis of examination of production ability, different market players, the general revenue created by every player of the Canine Stem Cell Therapy market, and manufacturing chain of market all over the world, regional analysis, and so on. Various methodical factors such as asset returns, probability, and examination of current status of market has been employed in the research to offer a full data of the Canine Stem Cell Therapy market

There are 15 Chapters to display the Global Canine Stem Cell Therapy market

Chapter 1, Definition, Specifications and Classification of Canine Stem Cell Therapy, Applications of Canine Stem Cell Therapy, Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Canine Stem Cell Therapy, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Canine Stem Cell Therapy Segment Market Analysis (by Type);Chapter 7 and 8, The Canine Stem Cell Therapy Segment Market Analysis (by Application) Major Manufacturers Analysis of Canine Stem Cell Therapy ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Allogeneic Stem Cells, Autologous Stem cells, Market Trend by Application Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Canine Stem Cell Therapy ;Chapter 12, Canine Stem Cell Therapy Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Canine Stem Cell Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: http://www.reportsbuzz.com/inquiry-for-buying.html?repid=74282

Reasons for Buying Canine Stem Cell Therapy market

This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Sorry! The Author has not filled his profile.

More here:
Global Canine Stem Cell Therapy Market Data Analysis, Growth, Demand & Forecast 2019-2024: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus,...

Global Stem Cell Cartilage Regeneration Market Size, Development Plans and Forecast to 2028 – Analytics News

The objective of Stem Cell Cartilage Regeneration Market Report provides a complete decision-making overview including definition, market gains, key geographic regions and imminent Stem Cell Cartilage Regeneration industry peers for 2019-2028. Global Stem Cell Cartilage Regeneration Market report focus on and regional market, providing vital information on major players, major applications, major types, and etc. Data type include capacity, revenue, consumption, market share, production, gross margin, cost, price, growth rate, import, export etc. Industry chain, marketing channel, manufacturing process, cost structure are also analyzed in this report.

The main aim of this report is to help the user understand market share distribution of number of companies in the Stem Cell Cartilage Regeneration market. Along with overall market analysis and capacity details are also included in this research report. The regional segmentation helps the market players to understand where to make investments and where there will support from both the government and consumers.

Request for Sample Copy of Stem Cell Cartilage Regeneration Market Report @ https://marketresearch.biz/report/stem-cell-cartilage-regeneration-market/request-sample

Leading Players of Stem Cell Cartilage Regeneration Market Are:Theracell (Laboratories), Orthocell Limited, Xintela AB (publ), CellGenix GmbH, Merck KGaA, Osiris Therapeutics Inc, BioTissue Technologies GmbH, Vericel Corporation, Smith & Nephew plc, EMD Serono Inc

The Stem Cell Cartilage Regeneration Market Objectives Are:

To analyze and Concentration the global Stem Cell Cartilage Regeneration sales, value, status and forecast (2019-2028).

To analyze the top players in North America, Europe, China, Japan, Southeast Asia and India, to Concentration the sales, value and market share of top players in these regions.

Focuses on the key Stem Cell Cartilage Regeneration players, to Concentration the sales, value and development plans in future.

Focuses on the global key players, to define, describe and analyze the market competition landscape and SWOT analysis.

To define, describe and forecast the market by application, type, and region.

To analyze the global and key regions market potential and opportunity, advantage, and restraints, challenge and risks.

To determine significant trends and factors driving or inhibiting the growth of market.

To identify the opportunities in the market for stakeholders by analyzing the high growth segments.

To strategically analyze each sub-market with respect to separate growth trend and their contribution to the market.

To planned profile the key players and to analyze their growth strategies.

To analyze competitive developments such as agreements, new product launches, expansions, and acquisitions in the market.

Global Stem Cell Cartilage Regeneration Market Segmentation:Segmentation by stem cell type: Hematopoietic Stem Cells (HSCs), Pluripotent Stem Cells (iPSC/ESCs), Mesenchymal Stem Cells (MSCs). Segmentation by treatment: Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation, Stem Cell Injections. Segmentation by end user: Hospitals & Clinics, Ambulatory Surgical Centers

Questions Answered for Stem Cell Cartilage Regeneration Market:

There are many questions that we have in our mind when we think of the competition and unknown factors that invites cash burning, and we learn it the hard way. has counted those questions, and they used the market research report to answer the all-important questions of the Stem Cell Cartilage Regeneration Market.

What is the development rate of the Stem Cell Cartilage Regeneration Market in 2019-2028?

What will be the future market size of the Stem Cell Cartilage Regeneration Market?

Who are the top leading companies in the Stem Cell Cartilage Regeneration Market?

Who are global manufacturers in the Stem Cell Cartilage Regeneration Market?

What are the major Stem Cell Cartilage Regeneration Market Trends 2019-2028?

What are the challenges faced in the Stem Cell Cartilage Regeneration Market?

What are the conclusions of the Stem Cell Cartilage Regeneration Market report?

Inquire for further detailed information of Stem Cell Cartilage Regeneration Market Report @ https://marketresearch.biz/report/stem-cell-cartilage-regeneration-market/#inquiry

At the end, this Stem Cell Cartilage Regeneration Market report covers the current market scene and its development estimates over the coming years, the report additionally manages the extant cycle of item, partner it to the significant items among the ventures that had just been popularized subtle elements of the business.

Get in touch with us:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876

email:[emailprotected]

Read more here:
Global Stem Cell Cartilage Regeneration Market Size, Development Plans and Forecast to 2028 - Analytics News

Amyotrophic Lateral Sclerosis (Lou Gehrigs Disease) Treatment Market Size, Status and Growth Opportunities by 2016 2022 – Analytics News

Amyotrophic Lateral Sclerosis (ALS) is a neurological disease that affects nerve cells in the brain and spinal cords which controls the activity of voluntary muscles. It is also termed as Lou Gehrigs disease. There are several causes behind ALS which includes gene mutation, disorganized immune response, chemical imbalance etc. The symptoms for ALS mainly include fasciculation, respiratory problems, muscles weakness and cramps. The mortality rate in the ALS patients in high due to breathing problem. ALS disease is rare and affect 1 or 2 out of 100,000 people across the globe.

Increasing in the number of patients affected with ALS is one of the major factor to drive the growth of ALS treatment market. Sporadic and familial are two types of ALS disease, in which sporadic disease is most common disease found with 9095% of the overall cases in US and the government initiatives to examination the research for rare disease and FDA approvals creates an opportunity for various market players due to which the global market of amyotrophic lateral sclerosis treatment is expected to expand at healthy CAGR during the forecast period. Due to lower prevalence rate, awareness about the disease and low treatment availability hinder the growth of ALS treatment market.

Amyotrophic lateral sclerosis treatment market has been classified on the basis of drug, treatment, and distribution channel:

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/9626?source=atm

Amyotrophic lateral sclerosis treatment by drug type: Riluzole Nuedexta

Amyotrophic lateral sclerosis treatment by treatment type: Chemotherapy Stem cell therapy

Amyotrophic lateral sclerosis treatment by distribution channel: Hospitals Diagnostic centres Clinics Retail Pharmacies

The competition in the ALS treatment market is weak due to the presence of only one drug in the market. Riluzole is the only drug which is approved by FDA and dominating the market which increase the patients survival rate. Also, ALS low efficacy, high cost and moderate safety of therapy constrains the utilization of the Riluzole drug. Rise in the ageing population worldwide would enlarge the development of ALS treatment market. The Collaborative ALS Drug Discovery Initiative (CADDI) and government regulations have taken initiative to accelerate the new drug development and treatments for ALS, which will further increase the number of pipeline drugs.

Request to view TOC at https://www.persistencemarketresearch.com/toc/9626?source=atm

Depending on geographic region, amyotrophic lateral sclerosis treatment market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America is estimated to contribute maximum revenue share in the global market of amyotrophic lateral sclerosis treatment followed by Europe. Asia Pacific regions are expected to grow at a higher growth rate owing to high occurrence of ALS diseases. The developing nations in Asia Pacific, Middle East and Africa hold huge potential for growth in the global amyotrophic lateral sclerosis treatment, due to large number of surgical procedures in these regions.

Key players of amyotrophic lateral sclerosis treatment market are GNT Pharma, Amkor Pharma, Synthetic Biologics, Mitsubishi Tanabe Pharma, Avicena inc, sanofi, and generic versions are manufactured by Apotex Corp, Mylan Pharmaceuticals Inc, Impax Laboratories.

The report covers exhaustive analysis on: Amyotrophic Lateral Sclerosis Treatment Market Segments Amyotrophic Lateral Sclerosis Treatment Market Dynamics Historical Actual Market Size, 2013 2015 Amyotrophic Lateral Sclerosis Treatment Market Size & Forecast 2016 to 2022 Amyotrophic Lateral Sclerosis Treatment Market Current Trends/Issues/Challenges Competition & Companies involved Amyotrophic Lateral Sclerosis Treatment Market Drivers and Restraints

Regional analysis includes North America Latin America Europe Asia Pacific The Middle East and Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/9626?source=atm

See the rest here:
Amyotrophic Lateral Sclerosis (Lou Gehrigs Disease) Treatment Market Size, Status and Growth Opportunities by 2016 2022 - Analytics News